Patents Assigned to Perseus Proteomics Inc.
-
Publication number: 20120136140Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.Type: ApplicationFiled: April 30, 2010Publication date: May 31, 2012Applicants: PERSEUS PROTEOMICS INC., THE UNIVERSITY OF TOKYOInventors: Hiroyuki Aburatani, Lilin Zhang, Keisuke Ishi, Katsushi Kouda, Aya Sakamoto, Keiko Katsumi, Hiroshi Onishi, Yoko Kayukawa
-
Publication number: 20120128694Abstract: To provide a therapeutic drug for Alzheimer's disease and/or a cancer. The therapeutic drug for Alzheimer's disease and/or a cancer contains an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative.Type: ApplicationFiled: October 19, 2011Publication date: May 24, 2012Applicants: PERSEUS PROTEOMICS INC., THE UNIVERSITY OF TOKYOInventors: TAKESHI IWATSUBO, TATSUHIKO KODAMA, TAKAO HAMAKUBO, TAISUKE TOMITA, IKUO HAYASHI, YASUOMI URANO, HIROKO IWANARI, MASAO OHKUCHI
-
Publication number: 20120039879Abstract: It is an object of the present invention to provide a mutant streptavidin wherein the immunogenicity (antigenicity) in mammals of a streptavidin is reduced. The present invention provides a mutant streptavidin, which comprises an amino acid sequence in which (a) the arginine residue at position 72 is substituted with another amino acid residue, and (b) any one or more of the tyrosine residue at position 10, the tyrosine residue at position 71, the glutamic acid residue at position 89, the arginine residue at position 91, and the glutamic acid residue at position 104 are substituted with other amino acid residues, with respect to the amino acid sequence of a core streptavidin as shown in SEQ ID NO: 2, and which has decreased immunogenicity as compared with that of a wild-type streptavidin.Type: ApplicationFiled: February 19, 2010Publication date: February 16, 2012Applicants: PERSEUS PROTEOMICS INC., THE UNIVERSITY OF TOKYOInventors: Tatsuhiko Kodama, Takao Hamakubo, Hirofumi Doi, Akira Sugiyama, Kouhei Tsumoto
-
Publication number: 20120034706Abstract: Provided a method for correctly assessing an inflammatory condition of a patient who is receiving a therapy with an IL-6 inhibitor. The method for assessing an inflammatory condition of a patient who is receiving an IL-6 inhibitor, including determining a PTX3 level of a sample derived from a patient who is receiving an IL-6 inhibitor.Type: ApplicationFiled: December 9, 2010Publication date: February 9, 2012Applicants: HAKUJYUJIKAI MEDICAL INC., Perseus Proteomics Inc.Inventors: Yukitaka Ueki, Nobuhito Masuda, Kyoko Miyamoto, Chihiro Miyazawa, Yukio Sudo
-
Publication number: 20110288278Abstract: The present invention provides a novel diagnostic or therapeutic method for pancreatic cancer employing a blood marker. The present invention provides a diagnostic or therapeutic drug for pancreatic cancer containing an anti-AMIGO2 antibody.Type: ApplicationFiled: July 14, 2011Publication date: November 24, 2011Applicants: The University of Tokyo, Perseus Proteomics Inc.Inventors: Hiroyuki Aburatani, Hiroko Iwanari, Isao Kohno
-
Publication number: 20110165179Abstract: To provide a therapeutic drug for Alzheimer's disease and/or a cancer. The therapeutic drug for Alzheimer's disease and/or a cancer contains an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative.Type: ApplicationFiled: December 7, 2010Publication date: July 7, 2011Applicants: The University of Tokyo, Perseus Proteomics Inc.Inventors: Takeshi IWATSUBO, Tatsuhiko Kodama, Takao Hamakubo, Taisuke Tomita, Ikuo Hayashi, Yasuomi Urano, Hiroko Iwanari, Masao Ohkuchi
-
Patent number: 7955807Abstract: To provide a method of determining vasculopathy, which is a risk factor of myocardial infarction, angiopathic dementia, etc., at an early stage thereof (i.e., mild vasculopathy). The present invention provides a method of determining the severity of mild vasculopathy, including determining PTX3 level in an assay sample by use of an anti-PTX3 monoclonal antibody.Type: GrantFiled: November 10, 2006Date of Patent: June 7, 2011Assignees: The University of Tokyo, Perseus Proteomics Inc.Inventors: Tatsuhiko Kodama, Takao Hamakubo, Koji Maemura, Akira Sugiyama, Hiroko Iwanari, Isao Kohno, Yukio Ito
-
Publication number: 20110082284Abstract: Disclosed are a protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a fragment thereof, an antibody recognizing the protein or antigen-binding fragment thereof, and a polynucleotide having a sequence comprising at least 12 consecutive nucleotides of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a nucleotide sequence complementary thereto. The gene and the protein of the invention is useful for diagnosing and treating cancer.Type: ApplicationFiled: August 31, 2010Publication date: April 7, 2011Applicants: ABURANTAI, Hiroyuki, Perseus Proteomics Inc., Chugai Seiyaku Kabushiki KaishaInventors: Hiroyuki Aburatani, Yoshitaka Hippo, Hirokazu Taniguchi, Yong xin Chen, Shumpei Ishikawa, Shin-ichi Fukumoto, Takahiro Shimamura, Naoko Kamimura, Ying qiu Guo, Shogo Yamamoto, Yukio Ito, Hirotaka Ito, Toshihiko Ohtomo
-
Patent number: 7875705Abstract: It is an object of the present invention to provide a novel antibody capable of specifically recognizing ROBO1 that is expressed in a cell membrane, a hybridoma that produces the above antibody, a method for producing the above antibody, and a tumor diagnostic agent used in PET comprising the above antibody. The present invention provides a monoclonal antibody capable of specifically recognizing ROBO1 existing on the surface of a cell, which is obtained by immunizing an animal to be immunized with a ROBO1-displaying budded baculovirus recovered from the culture supernatant of host cells infected with a recombinant baculovirus comprising the full-length cDNA of ROBO1 as an antigen.Type: GrantFiled: November 28, 2007Date of Patent: January 25, 2011Assignees: The University of Tokyo, Perseus Proteomics Inc.Inventors: Hiroko Iwanari, Isao Kohno, Takao Hamakubo, Yoshitaka Kumakura, Hirotaka Itoh, Toshiko Sakihama, Hiroyuki Aburatani, Toshimitsu Momose
-
Publication number: 20100316568Abstract: The present invention provides a novel diagnostic or therapeutic method for pancreatic cancer employing a blood marker. The present invention provides a diagnostic or therapeutic drug for pancreatic cancer containing an anti-AMIGO2 antibody.Type: ApplicationFiled: April 18, 2007Publication date: December 16, 2010Applicants: Perseus Proteomics Inc., The University of TokyoInventors: Hiroyuki Aburatani, Hiroko Iwanari, Isao Kohno
-
Patent number: 7691586Abstract: A method for prognosing possible recurrence after treatment of the liver cancer, characterized by measuring GPC3 contained in a test sample by use of an anti-GPC3 antibody.Type: GrantFiled: April 28, 2005Date of Patent: April 6, 2010Assignee: Perseus Proteomics Inc.Inventors: Kiyotaka Watanabe, Shin Ohnishi, Hiroyuki Aburatani, Yutaka Midorikawa, Yoshitaka Hippo, Hiroko Iwanari, Susumu Tokita, Hirokazu Satoh
-
Publication number: 20100062449Abstract: To provide a method of determining vasculopathy, which is a risk factor of myocardial infarction, angiopathic dementia, etc., at an early stage thereof (i.e., mild vasculopathy). The present invention provides a method of determining the severity of mild vasculopathy, including determining PTX3 level in an assay sample by use of an anti-PTX3 monoclonal antibody.Type: ApplicationFiled: November 10, 2006Publication date: March 11, 2010Applicants: The University of Tokyo, Perseus Proteomics Inc.Inventors: Tatsuhiko Kodama, Takao Hamakubo, Koji Maemura, Akira Sugiyama, Hiroko Iwanari, Isao Kohno, Yukio Ito
-
Publication number: 20100041167Abstract: The present invention is directed to a method for diagnosing large intestinal cancer and/or polyp and a method for observing postoperative course or monitoring recurrence thereof, wherein each method includes detecting cystatin SN protein by use of an anti-cystatin SN antibody. The present invention is able to provide a kit for assaying cystatin SN, which can be used, in a simple manner, in a diagnosis performed prior to conventional barium enema examination and endoscopic examination which impose burdens on patients; as an indicator of metastasis and recurrence; and in the evaluation of therapeutic effects. The present invention provides a method for diagnosing or monitoring large intestinal cancer and/or polyp which can be performed in a simple manner, and thus can allow to design a new regimen rapidly.Type: ApplicationFiled: December 14, 2005Publication date: February 18, 2010Applicants: Perseus Proteomics Inc., The University of TokyoInventors: Hiroyuki Aburatani, Takahiro Shimamura, Kiyotaka Watanabe, Takeharu Asano, Shin Ohnishi, Takao Hamakubo, Akira Sugiyama, Naoki Hosomi, Hiroko Iwanari, Keisuke Ishii
-
Publication number: 20090226918Abstract: Disclosed are a protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a fragment thereof, an antibody recognizing the protein or antigen-binding fragment thereof, and a polynucleotide having a sequence comprising at least 12 consecutive nucleotides of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a nucleotide sequence complementary thereto. The gene and the protein of the invention is useful for diagnosing and treating cancer.Type: ApplicationFiled: April 1, 2009Publication date: September 10, 2009Applicants: Perseus Proteomics Inc, Chugai Seiyaku Kabushiki KaishaInventors: Hiroyuki Aburatani, Yoshitaka Hippo, Hirokazu Taniguchi, Yong xin Chen, Shumpei Ishikawa, Shin-ichi Fukumoto, Takahiro Shimamura, Naoka Kamimura, Ying qiu Guo, Shogo Yamamoto, Yukio Ito, Hirotaka Ito, Toshihiko Ohtomo
-
Publication number: 20090220524Abstract: To provide a therapeutic drug for Alzheimer's disease and/or a cancer. The therapeutic drug for Alzheimer's disease and/or a cancer contains an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative.Type: ApplicationFiled: April 23, 2007Publication date: September 3, 2009Applicants: The University of Tokyo, Perseus Proteomics Inc.Inventors: Takeshi Iwatsubo, Tatsuhiko Kodama, Takao Hamakuob, Taisuke Tomita, Ikuo Hayashi, Yasuomi Urano, Hiroko Iwanari, Masao Ohkuchi
-
Publication number: 20090192108Abstract: Disclosed are a protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a fragment thereof, an antibody recognizing the protein or antigen-binding fragment thereof, and a polynucleotide having a sequence comprising at least 12 consecutive nucleotides of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a nucleotide sequence complementary thereto. The gene and the protein of the invention is useful for diagnosing and treating cancer.Type: ApplicationFiled: August 26, 2008Publication date: July 30, 2009Applicants: Perseus Proteomics Inc., Chugai Seiyaku Kabushiki KaishaInventors: Hiroyuki Aburatani, Yoshitaka Hippo, Hirokazu Taniguchi, Yong xin Chen, Shumpei Ishikawa, Shin-ichi Fukumoto, Takahiro Shimamura, Naoko Kamimura, Ying qiu Guo, Shogo Yamamoto, Yukio Ito, Hirotaka Ito, Toshihiko Ohtomo
-
Publication number: 20090092544Abstract: It is an object of the present invention to provide a novel antibody capable of specifically recognizing ROBO1 that is expressed in a cell membrane, a hybridoma that produces the above antibody, a method for producing the above antibody, and a tumor diagnostic agent used in PET comprising the above antibody. The present invention provides a monoclonal antibody capable of specifically recognizing ROBO1 existing on the surface of a cell, which is obtained by immunizing an animal to be immunized with a ROBO1-displaying budded baculovirus recovered from the culture supernatant of host cells infected with a recombinant baculovirus comprising the full-length cDNA of ROBO1 as an antigen.Type: ApplicationFiled: November 28, 2007Publication date: April 9, 2009Applicants: THE UNIVERSITY OF TOKYO, PERSEUS PROTEOMICS INC.Inventors: Hiroko Iwanari, Isao Kohno, Takao Hamakubo, Yoshitaka Kumakura, Hirotaka Itoh, Toshiko Sakihama, Hiroyuki Aburatani, Toshimitsu Momose
-
Publication number: 20080153104Abstract: Disclosed are a protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a fragment thereof, an antibody recognizing the protein or antigen-binding fragment thereof, and a polynucleotide having a sequence comprising at least 12 consecutive nucleotides of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a nucleotide sequence complementary thereto. The gene and the protein of the invention is useful for diagnosing and treating cancer.Type: ApplicationFiled: August 6, 2004Publication date: June 26, 2008Applicants: HIROYUKI ABURANTAI, PERSEUS PROTEOMICS INC, CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Hiroyuki Aburatani, Yoshitaka Hippo, Hirokazu Taniguchi, Yong xin Chen, Shumpei Ishikawa, Shin-ichi Fukumoto, Takahiro Shimamura, Naoko Kamimura, Ying qiu Guo, Shogo Yamamoto, Yukio Ito, Hirotaka Ito, Toshihiko Ohtomo
-
Publication number: 20070037204Abstract: Disclosed are a protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a fragment thereof, an antibody recognizing the protein or antigen-binding fragment thereof, and a polynucleotide having a sequence comprising at least 12 consecutive nucleotides of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a nucleotide sequence complementary thereto. The gene and the protein of the invention is useful for diagnosing and treating cancer.Type: ApplicationFiled: October 20, 2006Publication date: February 15, 2007Applicants: Perseus Proteomics Inc., Chugai Seiyaku Kabushiki KaishaInventors: Hiroyuki Aburatani, Yoshitaka Hippo, Hirokazu Taniguchi, Yong Chen, Shumpei Ishikawa, Shin-ichi Fukumoto, Takahiro Shimamura, Naoko Kamimura, Ying Gou, Shogo Yamamoto, Yukio Ito, Hirotaka Ito, Toshihiko Ohtomo
-
Publication number: 20060014223Abstract: Provided is a method for diagnosing cancer by detecting a novel cancer marker. Cancer can be diagnosed by detecting soluble glypican 3 in a test sample.Type: ApplicationFiled: September 4, 2003Publication date: January 19, 2006Applicant: Perseus Proteomics Inc.Inventors: Hiroyuki Aburatani, Yutaka Midorikawa, Kiyotaka Nakano, Iwao Ohizumi, Yukio Ito, Susumu Tokita